REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult Participants
Metastatic Castration-Resistant Prostate Cancer · mCRPC
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.8
5 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 192 (planned)
- Started
- Jun 28, 2027
- Main results expected
- Jul 28, 2031
- Fully finished
- Jul 28, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Occurrence of Treatment Emergent Adverse Events (TEAEs)
Measured over: Up to 5 years
Occurrence of Dose-Limiting Toxicities (DLTs)
Measured over: Up to 42 days
Occurrence of Serious Adverse Events (SAEs)
Measured over: Up to 5 years
Occurrence of Adverse Events of Special Interests (AESIs)
Measured over: Up to 5 years
Composite Response Rate (CRR) of ≥50% decline of prostate specific antigen (PSA) and/or confirmed radiographic response of complete response (CR) or partial response (PR)
Measured over: Up to 5 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07850921 · record last updated 2026-09-30 · checked 2026-11-09 15:47 UTC